TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05050292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cognitive stimulation
Description: Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham cognitive stimulation
Description: Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game.
Study: NCT03560583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 10 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo 10 mg BID
Study: NCT05306353

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VIB4920
Description: 26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920 with TNFi
Description: 52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920 without TNFi
Description: Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
Study: NCT06387069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-306 Regimen
Description: Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Chemotherapy Regimen
Description: Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* MEC regimen: etoposide injection 100 mg/m2, cytarabine injection 1000 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: cytarabine injection 20 mg q12h SC or IV for 10 consecutive days (Days 1-10).~* Azacitidine: azacitidine injection 75 mg/m2 QD SC or IV for 7 consecutive days (Days 1-7).
Study: NCT06319209

Intervention type: OTHER
Intervention: Preoperative resolved COVID-19
Description: We observed postoperative outcomes only in patients who had or did not have COVID-19 before surgery, without any additional intervention.
Study: NCT04813978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
Study: NCT05006339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Monitoring
Description: Patients in this arm are not required to attend in-office retention appointments except if they have any problems with their retainers and when data collection is necessary. Instead they are required to submit scans of their teeth through the DM mobile application at the designated intervals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Review
Description: Patients in this arm are required to attend in clinic appointments for their retention review
Study: NCT05816369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste session of five ONS flavors
Description: Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
Study: NCT04971798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-free Stem Cell-derived Extract Formulation (CCM)
Description: Intraarticular injection
Study: NCT06253026

Intervention type: OTHER
Intervention: Search and rescue mission
Description: Air search and rescue missions lasting 15 consecutive days
Study: NCT04705311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
Study: NCT05816291

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Time to Exhaustion at velocity at VO2max
Description: During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Time to Exhaustion at velocity at VO2max
Description: During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
Study: NCT06359704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregivers Of dementia Processing Emotions (COPE) program
Description: a dual-modal (face-to-face and online approaches), client-customized Caregivers Of dementia Processing Emotions (COPE) program
Study: NCT04927260

Intervention type: DRUG
Intervention: Patient treated by Avapritinib in real life
Description: The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.~Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA.
Study: NCT05733260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 weeks of resistance training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 weeks of resistance training.
Study: NCT04705311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair rehabilitation
Description: Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair rehabilitation
Description: Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
Study: NCT06580730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical treatment
Description: Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician.
Study: NCT04373343

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 16-week Food Addiction Clinical Treatment (FACT) Program
Description: 16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
Study: NCT06419439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine hydrochloride
Description: Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
Study: NCT05054179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution Bolus
Description: 20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution Bolus
Description: 20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Infusion
Description: 3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution Infusion
Description: 3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
Study: NCT06287489

Intervention type: OTHER
Group type: OTHER
Intervention: Mediterranean diet
Description: Mediterranean diet for three month

Intervention type: OTHER
Group type: OTHER
Intervention: Mediterranean diet
Description: Mediterranean diet for three month
Study: NCT05970068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantation of hydrophobic tubes for edema fluid drainage
Description: 1 - A 2-cm-long incision is made at the border of the hypogastrium or lumbar region 10 cm above the inguinal crease; 2- A 1.5-cm-wide and 100-cm-long metal tube tunneling device is introduced under the skin and bluntly passed in the subcutaneous tissue toward the thigh and internal aspect of the calf; 3- Incisions 2 cm long are made in the groin and calf, through which the tunneling device was passed; 4-The hydrophobic tube is passed upward through the tunneling device, after which the tunneling device is removed; 5-The upper and lower ends of the hydrophobic tubes are fixed to the fascia with absorbable sutures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Best Medical Treatment
Description: Compressive therapy, Phisioterapy, venous intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Compressive therapy, Phisioterapy, venous intervention
Study: NCT06419439

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine hydrochloride
Description: Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimally Enhanced Usual Care
Description: Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Enhanced Usual Care
Description: Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief narrative intervention
Description: Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions.~Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief narrative intervention
Description: Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions.~Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention.
Study: NCT03938987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CD19-directed chimeric antigen receptor (CAR) T-cells
Description: Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
Study: NCT04996563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
Study: NCT06348641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: baby massage
Description: The infant massage to be applied before the examination will be applied by a single nurse=researcher. Video recordings will be taken before and during the ROP examination and evaluations will be made by two neonatal nurses other than the researcher.
Study: NCT05215678

Intervention type: OTHER
Intervention: Acceptance of invitation to trial participation
Description: Individuals who are eligible for and accept participation in the INKA trial (NCT05172843)
Study: NCT05277623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: the same amount of 0.9% normal saline
Study: NCT06287489

Intervention type: OTHER
Group type: OTHER
Intervention: Regular diet
Description: regular diet
Study: NCT06390644

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periorbital Massage Therapy
Description: Participants in this arm will receive periorbital massage therapy administered by a trained practitioner. The massage technique will involve gentle circular motions around the eye sockets and brow bone area, aiming to improve eyelid and tear gland function.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (Standard Care)
Description: Participants in this arm will receive standard care for dry eye disease, which include artificial tears. They will not receive periorbital massage therapy.
Study: NCT05813366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tryptophan-Rich Diet
Description: All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tryptophan-Rich Diet
Description: All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B6 Supplementation
Description: All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B6 Supplementation
Description: All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B6 Supplementation
Description: All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
Study: NCT05215678

Intervention type: OTHER
Intervention: Declining invitation to trial participation
Description: Individuals who are eligible for participation in the INKA trial (NCT05172843) but decline the invitation to participate
Study: NCT06020573

Intervention type: DEVICE
Group type: OTHER
Intervention: Clip-on electrode with fiber optics
Description: The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
Study: NCT05757479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Steroid-eluting stent implantation
Description: The sinus cavity with inflammation receives one bioabsorbable steroid-eluting sinus stent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid nasal spray
Description: 1 spray into each nostril once a day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasal saline rinses
Description: The saltwater runs through nasal passages and drains out of the nostril.
Study: NCT05739344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral approach based resilience development program for schizophrenic individuals
Description: The intervention will be administered as sessions of 2 hours once a week.
Study: NCT05385159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION
Description: Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
Study: NCT05320601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation
Description: Repetitive Peripheral Magnetic Stimulation at trigger point of upper trapezius muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling at trigger point of upper trapezius muscle
Study: NCT05757479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasal saline rinses
Description: The saltwater runs through nasal passages and drains out of the nostril.
Study: NCT06099353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Age
Description: Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.